Analytical Data
-
Gene name
ITGa5
- Application
-
Alternative Names
CD49e; CD49-E; ITG-A5; FNRA; VLA5A; Fibronectin Receptor,Alpha Polypeptide; Integrin alpha-F; CD49 antigen-like family member E
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A0G2K1E2
-
Expression Region
Asp516~Cys971
-
Molecular Weight
54&29kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ITGa5, or integrin alpha-5, is a crucial component of the integrin family, which plays a significant role in cell adhesion, migration, and signal transduction. Research on ITGa5 has gained traction due to its involvement in important biological processes and diseases, particularly in cancer and fibrotic disorders. It interacts with fibronectin, influencing extracellular matrix dynamics and cellular behavior. Dysregulation of ITGa5 has been linked to tumor progression and metastasis, making it a potential target for therapeutic intervention. Studies have employed recombinant ITGa5 proteins to investigate their structural and functional properties, revealing insights into their role in cell signaling pathways and their impact on cell fate. Advances in recombinant DNA technology have facilitated the production of ITGa5 variants, allowing for detailed analysis of its interactions and mechanisms. This research is pivotal for developing novel strategies to modulate ITGa5 activity in pathogenic conditions, thereby providing new avenues for treatment in cancer and other related diseases. As our understanding of ITGa5 continues to grow, its potential as a biomarker or therapeutic target offers promising prospects for improving patient outcomes in various pathological contexts.
